A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
Status:
Withdrawn
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study combines two drugs (ruxolitinib and the tyrosine kinase inhibitor, nilotinib) in
an attempt to eliminate the CML (Chronic Myeloid Leukemia) stem cell population and thus
allow for the deepest and most durable response possible in patients with CML in chronic
phase who have achieved a complete hematologic remission (CHR), complete cytogenetic
remission (CCyR), and major molecular remission (MMR), but not a complete molecular remission
(CMR). The study will look at safety and tolerability of ruxolitinib when combined with
nilotinib in a phase I study and will help establish the MTD (Maximum Tolerated Dose) of
ruxolitinib when combined with nilotinib. Once the optimal dose of ruxolitinib is established
in the phase I setting, a phase II evaluation will seek to establish the efficacy of this
combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center